Iovance Biotherapeutics, Inc. (IOVA) has a consensus analyst rating of Buy, based on 20 analysts covering the stock. Of those, 15 recommend buying, 5 recommend holding, and 0 recommend selling.
The analyst consensus price target for IOVA is $2.00, representing a -45.1% downside from the current price of $3.64. Price targets range from a low of $2.00 to a high of $2.00.
